Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12617001642370
Ethics application status
Approved
Date submitted
28/09/2017
Date registered
19/12/2017
Date last updated
8/12/2024
Date data sharing statement initially provided
3/04/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
A study looking at the use of Mfolfirinox Chemotherapy And Stereotactic Radiotherapy for Patients with Locally Advanced pancreatic cancer to evaluate if this is a feasible treatment option with acceptable acute toxicity rates.
Scientific title
Mfolfirinox And STEreotactic Radiotherapy for Patients with Locally Advanced paNcreatic cancer (MASTERPLAN Pilot): a feasibility study to assess if mFOLFIRINOX chemotherapy and Stereotactic Body Radiation Therapy (SBRT) is a feasible neoadjuvant treatment option with acceptable acute toxicity rates for patients with Borderline Resectable Pancreatic Adenocarcinoma (BRPC) or Unresectable Pancreatic Adenocarcinoma (UPC)
Secondary ID [1] 292975 0
Nil
Universal Trial Number (UTN)
U1111-1202-7476
Trial acronym
MASTERPLAN (Pilot)
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Borderline Resectable Pancreatic Adenocarcinoma 304876 0
Unresectable Pancreatic Adenocarcinoma 305317 0
Condition category
Condition code
Cancer 304188 304188 0 0
Pancreatic

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The intervention involved in this study are;
- four cycles of mFOLFIRINOX chemotherapy (standard of care). This involves Oxaliplatin (75mg/m2) via intravenous administration, Irinotecan(150mg/m2) via intravenous administration, 5-fluorouracil (2400mg/m2) via continuous infusion over 4 days. This is done 4 times every 14 days. The chemotherapy is prescribed by a qualified medical oncologist and delivered by a qualified registered nurse.
- insertion of fiducial markers used for imaging during radiotherapy which is performed more than 3 days before the commencement of SBRT. Fiducial markers that aid in the visualisation of the tumour during radiotherapy will be inserted prior to SBRT. The fiducial markers will be placed either percutaneously (needle puncture of the skin), intraoperatively (during surgery), or under Endoscopic ultrasound (EUS) guidance. The method used will depend on tumour location. This only needs to be performed at one time point. This will take approximately 30 minutes to complete.
- SBRT will follow the completion of the four cycles of mFOLFIRINOX chemotherapy, SBRT will commence 2-4 weeks following the completion of mFOLFIRINOX chemotherapy based on clinician discretion. SBRT involves 5 treatments given over 2 to 3 weeks (depending on machine availability) to a dose of 30-45Gy. Patients are permitted to have treatment on two consecutive days but not three. Each SBRT treatment will take approximately 30 to 40 minutes each session. Dose per fraction will be 6 to 9Gy pending the location of the tumour. SBRT is prescribed by a qualified radiation oncologist and the SBRT is delivered by a qualified radiation therapist.
- surgery (if cancer is resectable after chemotherapy and SBRT),
- study blood tests. Study blood tests will be performed at baseline prior to chemotherapy, prior to cycle 2 , 3 and 4 of chemotherapy, prior to SBRT, 4 weeks following SBRT and at 3, 6, 12, 18 and 24 months following SBRT. These tests will require 35ml of blood to be taken (just over two tablespoons of blood).
- Positron Emission Tomography (PET) imaging using 18F-MISO and 18FDG-PET (approximately 4 hours each), The PET scans (both the 18F-MISO and FDG-PET) involves the use of an intravenously administered radioactive drug (tracer) followed by the scan. The PET-CT scan will be performed by a suitably qualified allied health professional. The 18FDG-PET is performed at baseline as standard of care and the performed as a study procedure prior to SBRT and 4 weeks after completion of SBRT. The 18F-MISO PET is completed only as a study procedure at baseline, prior to SBRT and 4 weeks after completion of SBRT if available.
- Magnetic Resonance Imaging (MRI). The MRI scans will be performed before and in the follow up stage after radiotherapy treatment over approximately a 24 month period. This includes MRI scans performed at least one week prior to radiotherapy treatment, and then 3, 6, 12, 18 and 24 months after radiotherapy treatment is finished. ALL MRI scans performed before or after the radiotherapy treatment are for the assessment of tumour and treatment response. The MRI scans will involve the use of a contrast agent administered intravenously by the treating doctor, unless contraindicated then no contrast will be used. The MRI scan will be performed by a suitably qualified allied health professional.
- completion of quality of life (QoL) questionnaires. QoL questionnaires will be completed by the participant at baseline, prior to SBRT, 6 weeks after SBRT, 3 months after SBRT and 6 months after SBRT. Subsequently QOL will be completed 6 monthly up until and including the 18 month follow up appointment.

The use of mFOLFIRINOX chemotherapy and SBRT in isolation has been tested but this study is testing the feasibility when they are combined.

For the investigational PET imaging and MRI scans performed at baseline, prior to SBRT and 4 weeks following SBRT, these will be performed within a few days of each other at the same hospital but in different departments. All investigational blood tests will be performed on the same day as the routine clinic visit.
The clinical trials team will document compliance of attendance at scheduled imaging. Patients who have not attended their scheduled imaging will be contacted by the clinical trials team and reasons for failure to attend will be sought. Where possible, attendance to reschedule appointments will be facilitated.
Intervention code [1] 299220 0
Treatment: Other
Comparator / control treatment
No control group - all patients will receive the same investigations.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 303502 0
To assess if mFOLFIRINOX chemotherapy and SBRT is a feasible neoadjuvant treatment option with acceptable acute toxicity rates for patients with BRPC or UPC.
This will be assessed by the EORTC QLQ-C30 and PAN26 QoL and toxicity data as per CTCAE V4 criteria.
Timepoint [1] 303502 0
6 weeks following completion of SBRT and then 3 monthly following SBRT for 1 year then 6 monthly for another year,
Secondary outcome [1] 339087 0
Response rates with neoadjuvant mFOLFIRINOX and SBRT as per RECIST criteria.
Timepoint [1] 339087 0
6 weeks following completion of SBRT and then 3 monthly following SBRT for 1 year then 6 monthly for another year,
Secondary outcome [2] 339088 0
Acute and late side effects with neoadjuvant mFOLFIRINOX and SBRT. Known side effects from mFOLFIRINOX include include gastrointestinal, neurological, myelosuppression, cutaneous manifestations and death. Known acute side effects from SBRT include nausea, vomiting, fatigue, gastritis, weight loss, anorexia and diarrhoea and know late side effects include haemorrhage, gastritis, ulceration, perforation, obstruction, gastroparesis and pancreatic insufficiency. All toxicity will be assessed using CTCAE version 4.
Timepoint [2] 339088 0
6 weeks following completion of SBRT and then 3 monthly following SBRT for 1 year then 6 monthly for another year,
Secondary outcome [3] 339090 0
Margin negative resection rates after neoadjuvant mFOLFIRINOX and SBRT
Timepoint [3] 339090 0
Margin negative resection rate is determined from pathology specimen with margin >1mm considered to be a negative resection margin. This is assessed directly from the pathology report following surgery.
Secondary outcome [4] 339091 0
1 year disease-free survival rates after neoadjuvant mFOLFIRINOX and SBRT. This will be assessed by clinical assessment.
Timepoint [4] 339091 0
12 months following completion of SBRT.
Secondary outcome [5] 339092 0
Assess qualitatively the functional Magnetic Resonance Imaging (MRI) changes of the pancreas at different time points during neoadjuvant treatment with mFOLFIRINOX and SBRT
Timepoint [5] 339092 0
Prior to SBRT and 4 weeks following completion of SBRT
Secondary outcome [6] 339095 0
Assess the variation in position of fiducial markers inserted into the pancreas during a course of SBRT
Timepoint [6] 339095 0
During SBRT treatment delivery via imaging modalities on the treatment machine including 4D cone beam CT at every fraction of SBRT.
Secondary outcome [7] 339096 0
Assess the changes in 18FDG uptake in patients diagnosed with pancreatic adenocarcinoma receiving mFOLFIRINOX and SBRT
Timepoint [7] 339096 0
Prior to any treatment, prior to SBRT and 4 weeks following completion of SBRT via measurement of total lesional glycolysis (TLG) and maximum standardised uptake value (SUV).
Secondary outcome [8] 339097 0
Assess the changes in tumour hypoxia in patients diagnosed with pancreatic adenocarcinoma receiving mFOLFIRINOX and SBRT
Timepoint [8] 339097 0
Prior to any treatment, prior to SBRT and 4 weeks following completion of SBRT via measurement of maximum SUV.
Secondary outcome [9] 340267 0
Treatment completion rates with neoadjuvant mFOLFIRINOX and SBRT
Timepoint [9] 340267 0
At the completion of neoadjuvant mFOLFIRINOX and SBRT.
Secondary outcome [10] 340268 0
1 year overall survival rates after neoadjuvant mFOLFIRINOX and SBRT. This will be assessed by clinical assessment.
Timepoint [10] 340268 0
12 months following completion of SBRT.
Secondary outcome [11] 341220 0
2 year disease-free survival rates after neoadjuvant mFOLFIRINOX and SBRT. This will be assessed by clinical assessment.
Timepoint [11] 341220 0
24 months following completion of SBRT.
Secondary outcome [12] 341221 0
2 year overall survival rates after neoadjuvant mFOLFIRINOX and SBRT. This will be assessed by clinical assessment.
Timepoint [12] 341221 0
24 months following completion of SBRT.

Eligibility
Key inclusion criteria
Age greater than or equal to 18 years and able to give informed consent.
Patients with histologically confirmed adenocarcinoma of the pancreas that is classified as BRPC or UPC, as per NCCN guidelines.
ECOG performance status 0 or 1.
Adequate bone marrow function (absolute neutrophil count ((ANC) greater than 1.5, platelets greater than 100).
Adequate liver function (albumin greater than 25 g/L, bilirubin less than or equal to 26 micromol/L; transaminases (ALT/AST) less than or equal to 5 times the upper limit of normal (ULN)).
Adequate renal function (creatinine less than or equal to 1.5 times the ULN).
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Age 70 years and over.
Patients with resectable or metastatic pancreatic cancer.
Neuroendocrine pancreatic carcinoma.
Previous chemotherapy or abdominal radiotherapy.
Previous diagnosis of cancer within the last 5 years (excluding non-melanoma skin cancers, and carcinoma in situ).
Chronic diarrhoea or peripheral neuropathy equal to or greater than grade 2.
Pregnancy.
Non-controlled coronary artery disease or myocardial infarction within the last 6 months.
Known hypersensitivity to 5-fluorouracil, irinotecan, oxaliplatin, capecitabine.
Patient will be ineligible for fMRI if they have contraindication to MRI. They will still have other imaging performed (18FDG-PET and 18F-MISO).
Patients with portal hypertension, coagulopathy or an inaccessible portal vein will not have portal vein blood sampling done as part of CTC/cPSC sub-study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
This feasibility study is only recruiting 10 participants who will all receive the mFOLFIRINOX and SBRT. There is no randomisation. No statistical justification of patient numbers has been undertaken.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
9/04/2018
Actual
5/04/2018
Date of last participant enrolment
Anticipated
9/04/2020
Actual
1/11/2019
Date of last data collection
Anticipated
30/06/2022
Actual
29/04/2022
Sample size
Target
10
Accrual to date
Final
11
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 9108 0
Liverpool Hospital - Liverpool
Recruitment hospital [2] 9109 0
Campbelltown Hospital - Campbelltown
Recruitment hospital [3] 9110 0
Bankstown-Lidcombe Hospital - Bankstown
Recruitment postcode(s) [1] 17608 0
2170 - Liverpool
Recruitment postcode(s) [2] 17609 0
2560 - Campbelltown
Recruitment postcode(s) [3] 17610 0
2200 - Bankstown

Funding & Sponsors
Funding source category [1] 297601 0
Hospital
Name [1] 297601 0
Liverpool Cancer Services Trust Fund
Country [1] 297601 0
Australia
Primary sponsor type
Hospital
Name
Liverpool Hospital
Address
1 Elizabeth St, Liverpool NSW 2170
Country
Australia
Secondary sponsor category [1] 296615 0
Individual
Name [1] 296615 0
Dr Andrew Oar
Address [1] 296615 0
Liverpool Cancer Therapy
Liverpool Hospital
1 Campbell St Liverpool
NSW 2170
Country [1] 296615 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 298694 0
South Western Sydney Local Health District
Ethics committee address [1] 298694 0
Ethics committee country [1] 298694 0
Australia
Date submitted for ethics approval [1] 298694 0
21/08/2017
Approval date [1] 298694 0
03/10/2017
Ethics approval number [1] 298694 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 77914 0
Dr Mark Lee
Address 77914 0
Liverpool Cancer Therapy Centre,
Locked Bag 7103
Liverpool BC
1871 NSW
Country 77914 0
Australia
Phone 77914 0
+61 2 8738 9806
Fax 77914 0
+61 2 8738 9811
Email 77914 0
mark.lee2@health.nsw.gov.au
Contact person for public queries
Name 77915 0
Andrew Oar
Address 77915 0
Liverpool Cancer Therapy Centre,
Locked Bag 7103
Liverpool BC
1871 NSW
Country 77915 0
Australia
Phone 77915 0
+61 2 8738 9806
Fax 77915 0
+61 2 8738 9811
Email 77915 0
Andrew.Oar@health.nsw.gov.au
Contact person for scientific queries
Name 77916 0
Andrew Oar
Address 77916 0
Liverpool Cancer Therapy Centre,
Locked Bag 7103
Liverpool BC
1871 NSW
Country 77916 0
Australia
Phone 77916 0
+61 2 8738 9806
Fax 77916 0
+61 2 8738 9811
Email 77916 0
Andrew.Oar@health.nsw.gov.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Radiotherapy treatment plan including CT, structure, dose and plan files
When will data be available (start and end dates)?
Currently available and till the end of the study
Available to whom?
TROG
Available for what types of analyses?
RT treatment
How or where can data be obtained?
DICOM RT


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseThe first real-time intrafraction target position monitoring in pancreas SBRT on an Elekta linear accelerator.2021https://dx.doi.org/10.1007/s13246-021-01007-0
EmbaseThe delivered dose assessment in pancreas SBRT with the target position determined using an in-house position monitoring system.2022https://dx.doi.org/10.3389/fonc.2022.1009916
N.B. These documents automatically identified may not have been verified by the study sponsor.